Arcturus Therapeutics (ARCT) Misses Q1 EPS by 90c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($2.15), $0.90 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $2.13 million versus the consensus estimate of $2.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
• Beike (BEKE) PT Raised to $23 at Morgan Stanley